Chengdu Kanghong Pharmaceutical Group Co., Ltd

SZSE:002773 Stock Report

Market Cap: CN¥18.1b

Chengdu Kanghong Pharmaceutical Group Past Earnings Performance

Past criteria checks 5/6

Chengdu Kanghong Pharmaceutical Group has been growing earnings at an average annual rate of 23.2%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 5.4% per year. Chengdu Kanghong Pharmaceutical Group's return on equity is 14%, and it has net margins of 27.3%.

Key information

23.2%

Earnings growth rate

22.0%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate5.4%
Return on equity14.0%
Net Margin27.3%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

With EPS Growth And More, Chengdu Kanghong Pharmaceutical Group (SZSE:002773) Makes An Interesting Case

Dec 12
With EPS Growth And More, Chengdu Kanghong Pharmaceutical Group (SZSE:002773) Makes An Interesting Case

Insufficient Growth At Chengdu Kanghong Pharmaceutical Group Co., Ltd (SZSE:002773) Hampers Share Price

Sep 15
Insufficient Growth At Chengdu Kanghong Pharmaceutical Group Co., Ltd (SZSE:002773) Hampers Share Price

Here's Why We Think Chengdu Kanghong Pharmaceutical Group (SZSE:002773) Is Well Worth Watching

Jun 21
Here's Why We Think Chengdu Kanghong Pharmaceutical Group (SZSE:002773) Is Well Worth Watching

Chengdu Kanghong Pharmaceutical Group Co., Ltd's (SZSE:002773) Price Is Right But Growth Is Lacking After Shares Rocket 40%

May 12
Chengdu Kanghong Pharmaceutical Group Co., Ltd's (SZSE:002773) Price Is Right But Growth Is Lacking After Shares Rocket 40%

Lacklustre Performance Is Driving Chengdu Kanghong Pharmaceutical Group Co., Ltd's (SZSE:002773) Low P/E

Mar 27
Lacklustre Performance Is Driving Chengdu Kanghong Pharmaceutical Group Co., Ltd's (SZSE:002773) Low P/E

Revenue & Expenses Breakdown

How Chengdu Kanghong Pharmaceutical Group makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SZSE:002773 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 244,3701,1932,090505
30 Jun 244,3311,2122,082444
31 Mar 244,1651,1392,031417
31 Dec 233,9571,0451,943422
30 Sep 233,7569671,888398
30 Jun 233,5468851,807412
31 Mar 233,3798791,697388
01 Jan 233,3898971,710374
30 Sep 223,3925231,700661
30 Jun 223,4695381,760696
31 Mar 223,5864851,801866
01 Jan 223,6054211,7831,008
30 Sep 213,792-1961,9352,101
30 Jun 213,802-1841,9552,018
31 Mar 213,577-2131,9421,828
31 Dec 203,295-2701,8911,676
30 Sep 203,1967451,870256
30 Jun 203,1327121,845290
31 Mar 203,1736841,934286
31 Dec 193,2577181,974287
30 Sep 193,1457411,863266
30 Jun 193,0537251,820243
31 Mar 192,9347001,771244
31 Dec 182,9176951,763230
30 Sep 182,8707351,608257
30 Jun 182,8017211,507280
31 Mar 182,8446991,565224
31 Dec 172,7866441,594192
30 Sep 172,8096021,78187
30 Jun 172,7455521,8710
31 Mar 172,6585461,7900
31 Dec 162,5404971,7320
30 Sep 162,4344551,6720
30 Jun 162,3484441,5940
31 Mar 162,1974281,4720
31 Dec 152,0743941,3940
30 Sep 152,0163521,3510
30 Jun 151,8653151,2500
31 Mar 151,7712861,3990
31 Dec 141,6752731,1330
31 Dec 131,4773169730

Quality Earnings: 002773 has high quality earnings.

Growing Profit Margin: 002773's current net profit margins (27.3%) are higher than last year (25.8%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 002773's earnings have grown significantly by 23.2% per year over the past 5 years.

Accelerating Growth: 002773's earnings growth over the past year (23.3%) exceeds its 5-year average (23.2% per year).

Earnings vs Industry: 002773 earnings growth over the past year (23.3%) exceeded the Pharmaceuticals industry -2.5%.


Return on Equity

High ROE: 002773's Return on Equity (14%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 17:39
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Chengdu Kanghong Pharmaceutical Group Co., Ltd is covered by 14 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Weiya ZhangBOCI Research Ltd.
Yue GaoChangjiang Securities Co. LTD.
Ziyu HeChina International Capital Corporation Limited